Increasing Treatment Options Through Targeted Therapies
Treatment of eosinophilic gastrointestinal diseases (EGIDs) is evolving as researchers identify the molecular mechanisms driving inflammation and translate those discoveries into more targeted therapeutic strategies.
For eosinophilic esophagitis (EoE), treatment increasingly involves an individualized approach that may include proton pump inhibitors (PPIs), swallowed topical corticosteroids, dietary therapy and biologic therapy. Treatment selection depends on disease characteristics, prior response and patient preferences.
Research at Cincinnati Children's continues to define the importance of the thymic stromal lymphopoietin (TSLP) / type 2 inflammatory pathway in EoE, providing a scientific rationale for investigating therapies that target TSLP. Anti-TSLP therapy represents an emerging area of investigation, illustrating how advances in understanding disease mechanisms may lead to new treatment options.
Similar progress is occurring in eosinophilic gastritis (EoG), a rare EGID that currently has no FDA-approved therapies.
The DEGAS randomized clinical trial of dupilumab in EoG demonstrated substantial reductions in gastric eosinophilic inflammation and improvements in histologic and endoscopic measures. Although symptom scores did not significantly differ between treatment and placebo groups at 12 weeks, the findings provide important evidence supporting type 2 inflammation as a therapeutic target in EoG.
Together, these developments reflect a broader shift from understanding the mechanisms underlying EGIDs to using those discoveries to develop and inform treatment strategies. For gastroenterologists, this evolving approach emphasizes the importance of considering disease characteristics, therapeutic response and emerging evidence when individualizing care.



